CoChat

Androgen Receptor Coregulators in Prostate Cancer

Open access
Rahman, Mujib, Miyamoto, Hiroshi, Chang, Chawnshang · 2004 · Clinical Cancer Research
Cited by 102

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

The transcriptional activity of androgen receptor (AR) is modulated by coregulators that have a significant influence on a number of functional properties of AR, including the ligand specificity as well as the DNA binding capacity. Because androgens and AR have pivotal roles in the development and growth of normal prostate as well as prostate cancer progression, these coregulators may significantly modulate the events of cancer development and progression. An aberrant regulation or expression of AR coregulators may contribute to androgen and AR-related diseases including prostate cancer. A precise understanding of the roles and mechanisms of individual coregulators may provide valuable information in designing rational therapy against prostate cancer. In this review, we analyzed the up-dated information regarding AR coregulators and their potential roles in prostate cancer progression.Androgens play essential roles in male sexual differentiation, sexual maturation, and the maintenance of spermatogenesis (1, 2). In addition to such vital roles in reproductive organ development, androgens also mediate physiological responses in a wide range of other tissues and organs including the skin, skeletal muscle, cardiac muscle, liver, kidney, central nervous system, and the hematopoietic system (3).The prostate gland is one of the main target organs for androgens, which mediate their biological responses through the AR, a Mr 110,000 ligand-inducible transcription factor that regulates tissue-specific expression of target genes. The AR belongs to the nuclear receptor (NR) superfamily, which also includes estrogen receptor, glucocorticoid receptor, progesterone receptor, vitamin D receptor, thyroid receptor, and retinoic acid receptor (4). It is ubiquitously expressed in human organs with the exception of the spleen and bone marrow, which show complete absence of AR expression. The AR gene is composed of eight exons encoding four functional domains similar to other members of the NR superfamily: a conserved DNA-binding domain, a hinge region, a COOH-terminal ligand-binding domain (LBD), and the less conserved NH2-terminal domain [A/B domain (5)]. Mutational and deletion analyses revealed two transcriptional activation functions including an NH2-terminal activation function (AF-1) involved in ligand-independent activation of AR and a ligand-dependent AF-2 function in the LBD. The AF-2 seems to be involved in more general transcriptional activity because mutation or deletion of the AF-2 domain dramatically reduces the transcriptional activation of AR (6, 7).Since cloning of its cDNA structure in 1988 (8), the AR has been extensively studied to elucidate its biological role in the development and progression of prostate cancer. The growth, differentiation, and maintenance of prostate tissue are dependent on AR and androgens, particularly testosterone and dihydrotestosterone (DHT). Overactivation of the AR signaling pathway may link to the progression of prostate cancer, which remains the most frequently diagnosed malignancy in aging men. Androgens and the AR play key roles in this malignancy, and each year about 30,000 men lose their lives to this malignancy in the United States (9). In 1941, Huggins and Hodges (10) first reported that the normal prostate and early stages of prostate cancer were highly dependent on androgens. Since then, androgen ablation, either by surgical castration or by pharmaco-logical/chemical castration, such as treatment with luteinizing hormone-releasing hormone analogs, has been the cornerstone of treatment in patients with locally advanced or metastatic prostate cancer. Androgen deprivation or the blockade of androgens at the level of the AR usually results in a favorable clinical response and a dramatic tumor regression (11, 12). Although complete disappearance of symptoms is achieved initially, in most cases the response does not imply cure. Upon continued treatment, the therapy fails, and most of the patients develop androgen-independent spread of the disease despite androgen ablation. At present there is no effective therapy for such an androgen-independent prostate cancer. One reason for failure of this androgen ablation therapy may be because of the presence of residual adrenal androgens in the circulation. Castration only abolishes testicular androgens, but the circulating adrenal androgens are readily available and can be converted to testosterone or DHT, the more active form of testosterone, in the prostate. To overcome this effect, antiandrogens are given in combination with castration (the so-called maximal androgen blockade therapy) to block the effects of androgens derived from the adrenals. However, support for additional benefit from this combined therapy is controversial, and a recent 5-year survival study failed to offer much hope for prostate cancer patients (13). Even after complete blockade of androgen action, the response to therapy is lost, tumors continue to grow, and th

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-0746-3

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 116

  1. Keller ET, Ershler WB, Chang C. The androgen receptor: a mediator of diverse responses. Front Biosci, 1: d59-71, 1996. · DOI · Paper page
  2. McLachlan RI, Wreford NG, O’Donnell L, de Kretser DM, Robertson DM. The endocrine regulation of spermatogenesis: independent roles for testosterone and FSH. J Endocrinol, 148: 1-9, 1996. · DOI · Paper page
  3. Tsai M-J, O’Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem, 63: 451-86, 1994. · DOI · Paper page
  4. MacLean HE, Warne GL, Zajac JD. Localization of functional domains in the androgen receptor. J Steroid Biochem Mol Biol, 62: 233-42, 1997. · DOI · Paper page
  5. Durand B, Saunders M, Gaudon C, et al Activation function 2 (AF-2) of retinoic acid receptor and 9-cis retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF-2 activity. EMBO J, 13: 5370-82, 1994. · DOI · Paper page
  6. Chang C, Kokontis J, Liao S. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science (Wash. DC), 240: 324-6, 1988. · DOI · Paper page
  7. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin, 52: 23-47, 2002. · DOI · Paper page
  8. Greyhack J, Keeler T, Kozlowski J. Carcinoma of the prostate: hormonal therapy. Cancer (Phila.), 60: 589-601, 1987. · DOI
  9. Prostate Cancer Trialist’s Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet, 355: 1491-8, 2000. · DOI · Paper page
  10. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst (Bethesda), 93: 1687-97, 2001. · DOI · Paper page
  11. Koivisto P, Visakorpi T, Rantala I, Isola J. Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer. J Pathol, 183: 51-6, 1997. · doi:10.1002/(sici)1096-9896(199709)183:1<51::aid-path1092>3.0.co;2-n
  12. Palmberg C, Koivisto P, Hyytinen E, et al Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol, 31: 216-9, 1997. · DOI
  13. Ishioka T, Tanatani A, Nagasawa K, Hashimoto Y. Anti-androgens with full antagonistic activity toward human prostate tumor LNCaP cells with mutated androgen receptor. Bioorg Med Chem Lett, 13: 2655-8, 2003. · DOI
  14. Steketee K, Timmerman L, Ziel-van der Made AC, et al Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer, 100: 309-17, 2002. · DOI · Paper page
  15. Krishnan AV, Zhao XY, Swami S, et al A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology, 143: 1889-900, 2002. · doi:10.1210/endo.143.5.8778
  16. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate, 42: 239-42, 2000. · DOI · Paper page
  17. Craft N, Shostak Y, Carey M, Sawyears C. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER2/ neu tyrosine kinase. Nat Med, 5: 280-5, 1999. · DOI · Paper page
  18. Yeh S, Lin H-K, Kang H-Y, et al From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cells. Proc Natl Acad Sci USA, 96: 5458-63, 1998. · DOI · Paper page
  19. Blok LJ, de Ruiter PE, Brinkmann AO. Androgen receptor phosphorylation. Endocr Res, 22: 197-219, 1996. · DOI · Paper page
  20. Ikonen T, Palvimo JJ, Kallio PJ, Reinikainen P, Janne OA. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation. Endocrinology, 135: 1359-66, 1994. · doi:10.1210/endo.135.4.7925097 · Paper page
  21. Katzenellenbogen JA, O’Malley BW, Katzenellenbogen BS. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol, 10: 119-31, 1996. · DOI · Paper page
  22. Mckenna NJ, Xu J, Nawaz J, et al Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol, 69: 3-12, 1999. · DOI · Paper page
  23. Onate SA, Tsai SY, Tsai MJ, O’Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science (Wash. DC), 270: 1354-7, 1995. · DOI · Paper page
  24. Voegel JJ, Heine M-J, Zechel C, Chambon P, Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J, 15: 3667-75, 1996. · DOI · Paper page
  25. Le Douarin B, Zechel C, Gamier J-M, et al The N-terminal part of TIF-1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein. EMBO J, 14: 2020-33, 1995. · DOI · Paper page
  26. Cavailles V, Dauvois S, L’Horset F, et al Nuclear factor RIP 140 modulates transcriptional activation by the estrogen receptor. EMBO J, 14: 3741-51, 1995. · DOI · Paper page
  27. Puigserver P, Wu Z, Park CW, et al A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell, 92: 829-39, 1998. · DOI · Paper page
  28. Moilanen AM, Poukka H, Karvonen U, et al Identification of a novel RING finger protein as a coregulator in steroid receptor-mediated gene transcription. Mol Cell Biol, 18: 5128-39, 1998. · DOI · Paper page
  29. Spencer TE, Jenster G, Burcin MM, et al Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (Lond.), 389: 194-8, 1997. · DOI · Paper page
  30. Fu M, Wang C, Reutens AT, et al p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem, 275: 20853-60, 2000. · DOI · Paper page
  31. Fu M, Wang C, Wang J, et al Androgen receptor acetylation governs transactivation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol, 22: 3373-88, 2002. · DOI · Paper page
  32. Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem, 277: 25904-13, 2002. · DOI · Paper page
  33. Yeh S, Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA, 93: 5517-21, 1996. · DOI · Paper page
  34. Kang H-Y, Yeh S, Fujimoto N, Chang C. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem, 274: 8570-6, 1999. · DOI · Paper page
  35. Fujimoto N, Yeh S, Kang H-Y, et al Isolation and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem, 274: 8316-21, 1999. · DOI · Paper page
  36. Poukka H, Karvonen U, Yoshikawa N, et al The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor. J Cell Sci, 113: 2991-3001, 2000. · DOI · Paper page
  37. Alen P, Claessens F, Schoenmakers E, et al Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1α with multiple steroid receptors and identification of an internally deleted ELE1β isoform. Mol Endocrinol, 13: 117-28, 1999. · DOI · Paper page
  38. Gao T, Brantley K, Bolu E, McPhaul MJ. RFG (ARA70, ELE1) interacts with the human androgen receptor in a ligand-dependent fashion, but functions only weakly as a coactivator in cotransfection assays. Mol Endocrinol, 13: 1645-56, 1999. · doi:10.1210/mend.13.10.0352 · Paper page
  39. Heinlein CA, Ting H-J, Yeh S, Chang C. Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor γ. J Biol Chem, 274: 16147-52, 1999. · DOI · Paper page
  40. Miyamoto H, Yeh S, Lardy H, Messing E, Chang C. Δ5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA, 95: 11083-8, 1998. · DOI · Paper page
  41. Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA, 95: 7379-84, 1998. · DOI · Paper page
  42. Miyamoto H, Chang C. Antiandrogens fail to block androstenedione-mediated mutated androgen receptor transactivation in human prostate cancer cells. Int J Urol, 7: 32-4, 2000. · DOI
  43. Zhou ZX, He B, Hall SH, Wilson EM, French FS. Domain interactions between coregulator ARA(70) and the androgen receptor (AR). Mol Endocrinol, 16: 287-300, 2002. · doi:10.1210/mend.16.2.0765 · Paper page
  44. Agoulnik I, Stenoien D, Mancini MA, Weigel N. Keystone Symposium, 2000, Nuclear Receptor Superfamily, Steamboat Springs, CO [abstract]. 302, 116.
  45. Agoulnik IU, Krause WC, Bingman WE, III, et al Repressors of androgen and progesterone receptor action. J Biol Chem, 278: 31136-48, 2003. · DOI · Paper page
  46. Han G, Foster BA, Mistry S, et al Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem, 276: 11204-13, 2001. · DOI · Paper page
  47. Rahman MM, Miyamoto H, Takatera H, et al Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells. J Biol Chem, 278: 19619-26, 2003. · DOI
  48. Taplin ME, Bubley GJ, Shuster TD, et al Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med, 332: 1393-8, 1995. · DOI · Paper page
  49. Culig Z, Hobisch A, Cronauer MV, et al Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol, 7: 1541-50, 1993. · DOI · Paper page
  50. Shibanuma M, Mashimo J, Kuroki T, Nose K. Characterization of the TGF β1-inducible hic-5 gene that encodes a putative novel zinc finger protein and its possible involvement in cellular senescence. J Biol Chem, 269: 26767-74, 1994. · DOI · Paper page
  51. Nishiya N, Sabe H, Nose K, Shibanuma M. The LIM domains of hic-5 protein recognize specific DNA fragments in a zinc-dependent manner in vitro. Nucleic Acids Res, 26: 4267-73, 1998. · DOI
  52. Yang L, Guerrero J, Hong H, DeFranco DB, Stallcup MR. Interaction of the tau2 transcriptional activation domain of glucocorticoid receptor with a novel steroid receptor coactivator, Hic-5, which localizes to both focal adhesions and the nuclear matrix. Mol Biol Cell, 11: 2007-18, 2000. · DOI · Paper page
  53. Wadman IA, Osada H, Grutz GG, et al The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J, 16: 3145-57, 1997. · DOI · Paper page
  54. Bach I, Carriere C, Ostendorff HP, Andersen B, Rosenfeld MG. A family of LIM domain-associated cofactors confer transcriptional synergism between LIM and Otx homeodomain proteins. Genes Dev, 11: 1370-80, 1997. · DOI · Paper page
  55. Fujimoto N, Mizokami A, Harada S, Matsumoto T. Different expression of androgen receptor coactivators in human prostate. Urology, 58: 289-94, 2001. · DOI
  56. Rahman MM, Miyamoto H, Lardy H, Chang C. Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proc Natl Acad Sci USA, 100: 5124-9, 2003. · DOI
  57. Miyamoto H, Rahman MM, Chang C. Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem, 91: 3-12, 2004. · DOI · Paper page
  58. Thomas SM, Hagel M, Turner CE. Characterization of a focal adhesion protein, Hic-5, that shares extensive homology with paxillin. J Cell Sci, 112: 181-90, 1999. · DOI · Paper page
  59. Matsuya M, Sasaki H, Aoto H, et al Cell adhesion kinase β forms a complex with a new member, Hic-5, of proteins localized at focal adhesions. J Biol Chem, 273: 1003-14, 1998. · DOI
  60. Wang X, Yang Y, Guo X, et al Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator. J Biol Chem, 277: 15426-31, 2002. · DOI · Paper page
  61. Stanzione R, Picascia A, Chieffi P, et al Variations of proline-rich kinase Pyk2 expression correlate with prostate cancer progression. Lab Investig, 81: 51-9, 2001. · DOI
  62. Avraham H, Park SY, Schinkmann K, Avraham S. RAFTK/Pyk2-mediated cellular signalling. Cell Signal, 12: 123-33, 2000. · DOI · Paper page
  63. Miyamoto H, Rahman M, Takatera H, et al A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. J Biol Chem, 277: 4609-17, 2002. · DOI
  64. Ito K, Adachi S, Iwakami R, et al N-terminally extended human ubiquitin-conjugating enzymes (E2s) mediate the ubiquitination of RING-finger proteins, ARA54 and RNF8. Eur J Biochem, 268: 2725-32, 2001. · DOI · Paper page
  65. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem, 67: 425-79, 1998. · DOI · Paper page
  66. Hsiao P-W, Chang C. Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells. J Biol Chem, 274: 22373-9, 1999. · DOI · Paper page
  67. Garcia JA, Ou SH, Wu F, et al Cloning and chromosomal mapping of a human immunodeficiency virus 1 “TATA” element modulatory factor. Proc Natl Acad Sci USA, 89: 9372-6, 1992. · DOI
  68. Wang X, Yeh S, Wu G, et al Identification and characterization of a novel androgen receptor coregulator ARA267-α in prostate cancer cells. J Biol Chem, 276: 40417-23, 2001. · DOI · Paper page
  69. Jenuwein T, Laible G, Dorn R, Reuter G. SET domain proteins modulate chromatin domains in eu- and heterochromatin. Cell Mol Life Sci, 54: 80-93, 1998. · DOI · Paper page
  70. Firestein R, Cui X, Huie P, Cleary ML. Set domain-dependent regulation of transcriptional silencing and growth control by SUV39H1, a mammalian ortholog of Drosophila Su(var)3–9. Mol Cell Biol, 20: 4900-9, 2000. · DOI · Paper page
  71. Cardoso C, Timsit S, Villard L, et al Specific interaction between the XNP/ATR-X gene product and the SET domain of the human EZH2 protein. Hum Mol Genet, 7: 679-84, 1998. · DOI · Paper page
  72. Cui X, De Vivo I, Slany R, et al Association of SET domain and myotubularin-related proteins modulates growth control. Nat Genet, 19: 331-7, 1998. · DOI · Paper page
  73. Huang N, vom Baur E, Garnier JM, et al Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators. EMBO J, 17: 3398-412, 1998. · DOI · Paper page
  74. Hsiao P-W, Lin D-L, Nakao R, Chang C. The linkage of Kennedy’s disease to ARA24, the first identified androgen receptor polyglutamine region-associated coactivator. J Biol Chem, 274: 20229-34, 1999. · DOI · Paper page
  75. Gorlich D, Kutay U. Transport between the cell nucleus and the cytoplasm. Annu Rev Cell Dev Biol, 15: 607-60, 1999. · DOI · Paper page
  76. Li P, Yu X, Ge K, et al Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol, 161: 1467-74, 2002. · DOI
  77. Kwiatkowski DJ. Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr Opin Cell Biol, 11: 103-8, 1999. · DOI · Paper page
  78. Stossel TP, Chaponnier C, Ezzell RM, et al Nonmuscle actin-binding proteins. Annu Rev Cell Biol, 1: 353-402, 1985. · DOI · Paper page
  79. Fujita H, Allen PG, Janmey PA, et al Induction of apoptosis by gelsolin truncates. Ann N Y Acad Sci, 886: 217-20, 1999. · doi:10.1111/j.1749-6632.1999.tb09420.x
  80. Koya RC, Fujita H, Shimizu S, et al Gelsolin inhibits apoptosis by blocking mitochondrial membrane potential loss and cytochrome c release. J Biol Chem, 275: 15343-9, 2000. · DOI · Paper page
  81. Dhanasekaran SM, Barrette TR, Ghosh D, et al Delineation of prognostic biomarkers in prostate cancer. Nature (Lond.), 412: 822-6, 2001. · DOI · Paper page
  82. Lee HK, Driscoll D, Asch H, Asch B, Zhang PJ. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate, 40: 14-9, 1999. · doi:10.1002/(sici)1097-0045(19990615)40:1<14::aid-pros2>3.0.co;2-6
  83. Pope RK, Pestonjamasp KN, Smith KP, et al Cloning, characterization, and chromosomal localization of human supervillin (SVIL). Genomics, 52: 342-51, 1998. · doi:10.1006/geno.1998.5466
  84. Ting H-J, Yeh S, Nishimura K, Chang C. Supervillin associates with androgen receptor and modulates its transcriptional activity. Proc Natl Acad Sci USA, 99: 661-6, 2002. · DOI · Paper page
  85. Pestonjamasp KN, Pope RK, Wulfkuhle JD, Luna EJ. Supervillin (p205): a novel membrane-associated, F-actin-binding protein in the villin/gelsolin superfamily. J Cell Biol, 139: 1255-69, 1997. · DOI
  86. Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. The androgen receptor can promote β-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem, 277: 17933-43, 2002. · DOI · Paper page
  87. Chesire DR, Ewing CM, Gage WR, Isaacs WB. In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis. Oncogene, 21: 2679-94, 2002. · DOI · Paper page
  88. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. Detection and analysis of β-catenin mutations in prostate cancer. Prostate, 45: 323-34, 2000. · DOI · Paper page
  89. Damalas A, Kahan S, Shtutman M, Ben-Ze’ev A, Oren M. Deregulated β-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J, 20: 4912-22, 2001. · DOI · Paper page
  90. Muscat GE, Burke LJ, Downes M. The corepressor N-CoR and its variants RIP13a and RIP13Delta1 directly interact with the basal transcription factors TFIIB, TAFII32 and TAFII70. Nucleic Acids Res, 26: 2899-907, 1998. · DOI · Paper page
  91. Heinzel T, Lavinsky RM, Mullen TM, et al A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature (Lond.), 387: 43-8, 1997. · DOI · Paper page
  92. Alland L, Muhle R, Hou H, Jr, et al Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature (Lond.), 387: 49-55, 1997. · DOI · Paper page
  93. Liao G, Chen LY, Zhang A, et al Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem, 278: 5052-61, 2003. · DOI · Paper page
  94. Reutens AT, Fu M, Wang C, et al Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol, 49: 797-811, 2001. · doi:10.1210/mend.15.5.0641 · Paper page
  95. Dedhar S, Rennie PS, Shago M, et al Inhibition of nuclear hormone receptor activity by calreticulin. Nature (Lond.), 367: 480-3, 1994. · DOI · Paper page
  96. Sharma M, Zarnegar M, Li X, Lim B, Sun Z. Androgen receptor interacts with a novel MYST protein, HBO1. J Biol Chem, 275: 35200-8, 2000. · DOI · Paper page
  97. Kang H-Y, Lin H-K, Hu Y-C, et al From transforming growth factor-β signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc Natl Acad Sci USA, 98: 3018-23, 2001. · DOI · Paper page
  98. Chipuk JE, Cornelius SC, Pultz NJ, et al The androgen receptor represses transforming growth factor-β signaling through interaction with Smad3. J Biol Chem, 277: 1240-8, 2002. · DOI · Paper page
  99. Kang H-Y, Huang K-E, Chang S-Y, et al Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. J Biol Chem, 277: 43749-56, 2002. · DOI · Paper page
  100. Massague J. Transforming growth factor-α. A model for membrane-anchored growth factors. J Biol Chem, 265: 21393-6, 1990. · DOI · Paper page
  101. Attisano L, Wrana JL, Lopez-Casillas F, Massague J. TGF-β receptors and actions. Biochim Biophys Acta, 122: 71-80, 1994. · DOI · Paper page
  102. Lamm ML, Sintich SM, Lee C. A proliferative effect of transforming growth factor-β1 on a human prostate cancer cell line, TSU-Pr1. Endocrinology, 139: 787-90, 1998. · DOI
  103. Wikstrom P, Damber J, Bergh A. Role of transforming growth factor-β1 in prostate cancer. Microsc Res Tech, 52: 411-9, 2001. · DOI
  104. Guo Y, Kyprianou N. Restoration of transforming growth factor β signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res, 59: 1366-71, 1999. · DOI
  105. Barrack ER. TGF β in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate, 31: 61-70, 1997. · DOI · Paper page
  106. Derynck R, Jarrett JA, Chen EY, et al Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature (Lond.), 316: 701-5, 1985. · DOI · Paper page
  107. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nat Med, 1: 282-4, 1995. · DOI · Paper page
  108. Adler HL, McCurdy MA, Kattan MW, et al Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol, 161: 182-7, 1999. · DOI · Paper page
  109. Chang C, Da Silva SL, Ideta R, et al Human and rat TR4 orphan receptors specify a subclass of the steroid receptor superfamily. Proc Natl Acad Sci USA, 91: 6040-4, 1994. · DOI
  110. Lee Y-F, Young W-J, Burbach JP, Chang C. Negative feedback control of the retinoid-retinoic acid/retinoid X receptor pathway by the human TR4 orphan receptor, a member of the steroid receptor superfamily. J Biol Chem, 273: 13437-43, 1998. · DOI
  111. Lee Y-F, Pan H-J, Burbach JP, Morkin E, Chang C. Identification of direct repeat 4 as a positive regulatory element for the human TR4 orphan receptor. A modulator for the thyroid hormone target genes. J Biol Chem, 272: 12215-20, 1997. · DOI
  112. Lee Y-F, Young W-J, Lin W-J, Shyr C-R, Chang C. Differential regulation of direct repeat 3 vitamin D3 and direct repeat 4 thyroid hormone signaling pathways by the human TR4 orphan receptor. J Biol Chem, 274: 16198-205, 1999. · doi:10.1074/jbc.274.23.16198
  113. Young W-J, Smith SM, Chang C. Induction of the intronic enhancer of the human ciliary neurotrophic factor receptor (CNTFRα) gene by the TR4 orphan receptor. A member of steroid receptor superfamily. J Biol Chem, 272: 3109-16, 1997. · DOI
  114. Lee Y-F, Shyr C-R, Thin TH, Lin W-J, Chang C. Convergence of two repressors through heterodimer formation of androgen receptor and testicular orphan receptor-4: a unique signaling pathway in the steroid receptor superfamily. Proc Natl Acad Sci USA, 96: 14724-9, 1999. · DOI · Paper page
  115. Zhang Y, Yang Y, Yeh S, Chang C. ARA67/PAT1 functions as a repressor to suppress androgen receptor transactivation. Mol Cell Biol, 24: 1044-57, 2004. · DOI
  116. Zheng P, Eastman J, Vande Pol S, Pimplikar SW. PAT1, a microtubule-interacting protein, recognizes the basolateral sorting signal of amyloid precursor protein. Proc Natl Acad Sci USA, 95: 14745-50, 1998. · DOI · Paper page

Cited by

See all 102

Metadata

Authors
Rahman, M., Miyamoto, H., & Chang, C.
Venue
Clinical Cancer Research
Published
2004-04-01
Volume
10
Issue
7
Pages
2208-2219
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2096870409
Cited by
102
References
14
FWCI
6.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Androgen Receptor Coregulators in Prostate Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-0746-3
The paper
Rahman, M., Miyamoto, H., & Chang, C. (2004). Androgen Receptor Coregulators in Prostate Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-0746-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.